Sugi Predict

Sugi Predict / Compounds / SCHEMBL633074

SCHEMBL633074

SCHEMBL633074

CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(Cl)c2)C1=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 10/20 0.67
▸ TSHR P16473 2/20 0.67
▸ SMN1; SMN2 Q16637 2/20 0.67
▸ MEN1 O00255 1/20 0.67
▸ LMNA P02545 1/20 0.67
▸ TP53 P04637 1/20 0.67
▸ CYP1A2 P05177 1/20 0.67
▸ PGR P06401 1/20 0.67
▸ CYP3A4 P08684 1/20 0.67
▸ CYP2D6 P10635 1/20 0.67
▸ CYP2C9 P11712 1/20 0.67
▸ ALOX12 P18054 1/20 0.67
▸ NFKB1 P19838 1/20 0.67
▸ CYP2C19 P33261 1/20 0.67
▸ RAB9A P51151 1/20 0.67
▸ KMT2A Q03164 1/20 0.67
▸ PDE4D Q08499 1/20 0.67
▸ NPSR1 Q6W5P4 1/20 0.67
▸ MAPK1 P28482 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11474265 0.89 AR (0.64) ARTSHRSMN1; SMN2MEN1LMNA
SCHEMBL94938 0.85 AR (0.69) ARTSHRSMN1; SMN2MEN1LMNA
SCHEMBL634133 0.82 AR (0.65) ARTSHRSMN1; SMN2MEN1LMNA
SCHEMBL3661785 0.81 AR (0.69) ARTSHRSMN1; SMN2MEN1LMNA
Nilutamide SCHEMBL29351021 0.81 AR (1.00) ARTSHRSMN1; SMN2MEN1LMNA
Nilutamide SCHEMBL1462011 0.81 AR (1.00) ARTSHRSMN1; SMN2MEN1LMNA
Nilutamide SCHEMBL12670 0.81 AR (1.00) ARTSHRSMN1; SMN2MEN1LMNA
Nilutamide SCHEMBL28562851 0.80 AR (0.98) ARTSHRSMN1; SMN2MEN1LMNA
SCHEMBL11463857 0.78 AR (0.59) ARTSHRSMN1; SMN2MEN1LMNA
SCHEMBL17571938 0.77 AR (0.64) ARTSHRSMN1; SMN2MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419422-B1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA SAS (FR) 2014-10-15 — — EP disclosed
CN-102428079-B Imidazolidine-2,4-dione derivatives and use thereof as a medicament IPSEN PHARMA SAS 2014-04-30 — — CN disclosed
US-8624037-B2 Imidazolidine-2,4-dione derivatives and use thereof as a medicament IPSEN PHARMA S.A.S. (FR) 2014-01-07 — — US disclosed
US-20120095068-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2012-04-19 — — US disclosed
EP-2419422-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2012-02-22 — — EP disclosed
WO-2010119194-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT IPSEN PHARMA S.A.S. (FR) 2010-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095068-A1 IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT MKI67, CCNI, CCNA1 AR 2479/4885TSHR 1622/4885SMN1; SMN2 1682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.